In the first experimental use of algorithms that employ structure-based
molecular modeling to optimize deimmunized drug candidates, Karl Griswold, PhD,
and co-investigator Christopher Bailey-Kellogg, PhD of Dartmouth College
complement their prior sequence-based deimmunizing algorithms and expand the
tool kit of protein engineering technologies to use in next generation drug
development.
Their paper, "Protein Deimmunization via Structure-based Design Enables
Efficient Epitope Deletion at High Mutational Loads," was published in Biotechnology
and Bioengineering.
Novel Technique to Develop Protein Drugs from Bacteria
A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield.
Advertisement
"This work is part of our larger collaborative initiative to develop performance-enhanced protein drugs that are invisible to the human immune system," explained Griswold. "Biotherapeutics offer potent treatment options for a wide range of diseases but, due to their biological origins, these powerful therapies can elicit detrimental immune responses in humans."
Development of biotherapeutic agents is a time-consuming and costly
endeavor, and there exists a substantial risk that deleterious immunogenicity
issues will undermine otherwise promising drug candidates late in the
development process. While methods for identifying immunogenic hotspots, or
epitopes, are evolving rapidly, technologies to redesign the hotspots while
maintaining biotherapeutic activity and stability are far less developed.
![E. Coli Bacteria Endows As A Factory For Sugar-Modified Proteins, Enabling Cheaper, Faster Pharmaceuticals]( "E. Coli Bacteria Endows As A Factory For Sugar-Modified Proteins, Enabling Cheaper, Faster Pharmaceuticals")
Escherichia coli, or e-coli bacteria deemed the curse of food safety by restaurateurs, grocers and consumers, is actually a pal.
This study used P99 betalactamase, a component of Antibody Directed Enzyme Prodrug Therapy, to show that structure-based deimmunization resulted in highly-active and stable biotherapeutic designs that were different from those generated with earlier sequence-based algorithms. In particular, the structure-based designs remodeled a putative immunogenic hotspot that was not readily addressed with other methods.
"We demonstrated that integrating molecular modeling into deimmunizing algorithms enables simultaneous redesign of numerous immunogenic hotspots distributed throughout a protein target," Bailey-Kellogg said. "These results suggest that even the most immunogenic drug candidates might be engineered for improved compatibility with the human immune system."
Dartmouth's team of Griswold and Bailey-Kellogg are turning their attention to advanced assays and methodologies to better assess the immunogenic potential of their deimmunized drug candidates. These methods should yield clinically relevant data showing the extent to which they have mitigated the immunogenicity risk of target proteins in the drug candidates.
Source: Medindia
E. Coli Bacteria Endows As A Factory For Sugar-Modified Proteins, Enabling Cheaper, Faster Pharmaceuticals
Escherichia coli, or e-coli bacteria deemed the curse of food safety by restaurateurs, grocers and consumers, is actually a pal.
Advertisement
This study used P99 betalactamase, a component of Antibody Directed Enzyme Prodrug Therapy, to show that structure-based deimmunization resulted in highly-active and stable biotherapeutic designs that were different from those generated with earlier sequence-based algorithms. In particular, the structure-based designs remodeled a putative immunogenic hotspot that was not readily addressed with other methods.
"We demonstrated that integrating molecular modeling into deimmunizing algorithms enables simultaneous redesign of numerous immunogenic hotspots distributed throughout a protein target," Bailey-Kellogg said. "These results suggest that even the most immunogenic drug candidates might be engineered for improved compatibility with the human immune system."
Dartmouth's team of Griswold and Bailey-Kellogg are turning their attention to advanced assays and methodologies to better assess the immunogenic potential of their deimmunized drug candidates. These methods should yield clinically relevant data showing the extent to which they have mitigated the immunogenicity risk of target proteins in the drug candidates.
Source: Medindia
Governer Demands Quality Check for Manufactured Drugs
Large number of drug samples lifted from various hospitals in Jammu and Kashmir were not of standard quality.
Advertisement
Advertisement
|
Advertisement
Latest Research News
Does omega-3 help Alzheimer's patients? A new form of omega-3 helped restore specific markers of eye health in mice bred with aspects of early-onset Alzheimer's disease.
Drugs used to inhibit the physiological responses for allergic reactions lessen osteoarthritis risk, revealed research.
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.